Oral Arginine Shows Promise as Cost-Effective Alzheimer's Treatment in Preclinical Studies

Researchers from Kindai University have discovered that oral administration of arginine, a naturally occurring amino acid, effectively suppresses amyloid-β (Aβ) aggregation and reduces toxic effects in animal models of Alzheimer's disease. The findings, published in Neurochemistry International, suggest that this clinically safe and inexpensive compound could offer a new therapeutic pathway for treating the progressive neurodegenerative disorder.

The research team, led by Professor Yoshitaka Nagai from the Department of Neurology at Kindai University Faculty of Medicine, demonstrated that arginine functions as a chemical chaperone, inhibiting the formation of Aβ42 aggregates that are central to Alzheimer's pathology. "Our study demonstrates that arginine can suppress Aβ aggregation both in vitro and in vivo," explains Prof. Nagai. "What makes this finding exciting is that arginine is already known to be clinically safe and inexpensive, making it a highly promising candidate for repositioning as a therapeutic option for AD."

Strong In Vitro Evidence of Aggregation Inhibition

Using in vitro assays, the researchers first demonstrated that arginine inhibits the formation of Aβ42 aggregates in a concentration-dependent manner. Co-incubation of Aβ42 peptides with arginine substantially reduced Thioflavin T fluorescence intensity, decreasing Aβ42 aggregation by 80% at 1 mM arginine concentration. Electron microscopy revealed that arginine treatment shortened amyloid fibrils, while biochemical analyses showed reduced insoluble Aβ42 fractions with unchanged soluble Aβ42 levels, consistent with reduced fibrillar aggregation.

Promising Results in Multiple Animal Models

Building on these laboratory findings, the team evaluated oral arginine in two established Alzheimer's disease models: a Drosophila model expressing Aβ42 with the Arctic mutation (E22G) and an AppNL-G-F knock-in mouse model carrying three familial AD mutations.

In the Drosophila model, Aβ42 expression in compound eyes led to abnormal deposition and eye shrinkage due to Aβ toxicity. However, oral arginine administration substantially decreased Aβ42 deposition and suppressed eye shrinkage in a dose-dependent manner.

The mouse studies provided even more compelling evidence. AppNL-G-F mice, which develop age-dependent Aβ deposition and behavioral abnormalities, received 6% arginine orally from 5 weeks of age. At six months, immunohistochemistry showed reduced Aβ deposition throughout the brain in arginine-treated mice, with quantitative analyses demonstrating fewer and smaller plaques in both the hippocampus and cortex.

Cognitive and Anti-Inflammatory Benefits

Beyond reducing amyloid pathology, arginine treatment produced meaningful functional improvements. AppNL-G-F mice typically demonstrate behavioral abnormalities in the Y-maze test, including fewer arm entries and reduced total distance traveled. Arginine-treated mice exhibited substantial improvements in arm entries and total distance at nine months, indicating better cognitive performance.

The therapeutic effects extended to neuroinflammation, a key pathological feature of Alzheimer's disease. Arginine-treated AppNL-G-F mice showed substantial reductions in pro-inflammatory cytokines including IL-1β (搜索)搜索该靶点, IL-6查看药品详情, and tumor necrosis factor, indicating that arginine mitigates Aβ-driven neuroinflammation.

Clinical Translation Potential

The researchers emphasize arginine's advantages for rapid clinical translation. Because arginine is already used clinically in Japan and has demonstrated high safety and brain permeability, it may overcome several early barriers faced by conventional drug development. This contrasts with current antibody-based therapies targeting amyloid β, which have limited clinical effectiveness, can be costly, and cause immune-related side effects.

"Our findings open up new possibilities for developing arginine-based strategies for neurodegenerative diseases caused by protein misfolding and aggregation," notes Prof. Nagai. "Given its excellent safety profile and low cost, arginine could be rapidly translated to clinical trials for Alzheimer's and potentially other related disorders."

Study Limitations and Future Directions

The researchers acknowledge important limitations in their findings. The studies were conducted in animal models with familial Arctic (E22G) mutations, which do not capture key features of human sporadic Alzheimer's disease, such as tau pathology or neuronal loss. Additionally, the researchers emphasized that although arginine is available as an over-the-counter dietary supplement, the dosage and administration protocol employed in this study was optimized for research purposes and does not correspond to commercially available formulations.

Further preclinical and clinical studies are needed to determine whether these therapeutic effects can be replicated in humans and to establish optimal dosing regimens. Nonetheless, the present findings provide compelling proof of concept that simple nutritional or pharmacological supplementation could mitigate amyloid pathology and improve neurological outcomes.

This research underscores the potential of drug repositioning—repurposing existing, safe compounds for new therapeutic uses—as an efficient pathway toward accessible Alzheimer's treatments. The study not only deepens understanding of Aβ aggregation dynamics but also highlights a readily implementable and cost-effective strategy that could ultimately benefit the growing global population affected by Alzheimer's disease.